Top

Magnetic Resonance Materials in Physics, Biology and Medicine

Published in:

01-02-2013 | Review Article

Radiotracers for positron emission tomography imaging

Author: Nic Gillings

Published in: Magnetic Resonance Materials in Physics, Biology and Medicine | Issue 1/2013

Abstract

The use of positron emission tomography for clinical diagnostics has grown rapidly over the past 2 decades. This growth has mainly been due to advances in scanner technology, and particularly the introduction of the combined PET/CT scanner, and has been based almost exclusively on one PET radiopharmaceutical ([¹⁸F]fluorodeoxyglucose), which is broadly applicable to cancer patients. The availability of radiopharmaceuticals and the clinical diagnostic potential of PET has also supported the continued development of the scanner technology. Due to the efforts of many researchers worldwide in the field of radiopharmaceutical sciences, we are now seeing an increasing number of radiopharmaceuticals used for routine clinical diagnostic imaging. This article is intended as a short educational review, giving a brief overview of the design, preparation and use of PET radiopharmaceuticals, with some examples of highly clinically relevant PET tracers.

International Atomic Energy Agency (2008) Cyclotron produced radionuclides: principles and practice, Technical Reports Series 465, Vienna

Clark C, Evans S, Marsden P, O’Donnell R, Pearson D (2011) Medical Cyclotrons (Including PET Radiopharmaceutical Production), Institute of Physics and Engineering in Medicine, 1st edn, ISBN-10: 1903613485

Phelps ME (ed) (2006) PET: Physics, Instrumentation, and Scanners. Spring Science + Business Media, LLC., New York

Russ Knapp FF, Baum RP (2012) Editorial: radionuclide generators—a new renaissance in the development of technologies to provide diagnostic and therapeutic radioisotopes for clinical applications. Curr Radiopharm 5(3):175–177CrossRef

International Atomic Energy Agency (2009) Technetium-99m radiopharmaceuticals: status and trends, IAEA radioisotopes and radiopharmaceuticals series 1, Vienna

Shetty D, Lee Y-S, Jeong JM (2010) ⁶⁸Ga-labeled radiopharmaceuticals for positron emission tomography. Nucl Med Mol Imaging 44:233–240CrossRef

Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP (2011) ⁶⁸Ga -labeled DOTA-peptides and ⁶⁸Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 41(4):314–321PubMedCrossRef

Prata MI (2012) Gallium-68: a new trend in PET radiopharmacy. Curr Radiopharm 5(2):142–149PubMedCrossRef

Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R, Thulkar S, Lata S, Malhotra A (2011) Role of ⁶⁸Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21(11):2408–2416PubMedCrossRef

10.

Yoshinaga K, Klein R, Tamaki N (2010) Generator-produced rubidium-82 positron emission tomography myocardial perfusion imaging—from basic aspects to clinical applications. J Cardiol 55:163–173PubMedCrossRef

11.

Valenta I, Schindler TH (2012) ⁸²Rb PET/CT: entering a new area of myocardial perfusion imaging? Eur J Nucl Med Mol Imaging 39(8):1231–1232PubMedCrossRef

12.

Ido T, Wan CN, Casella V, Fowler JS, Wolf AP, Reivich M, Kuhl DE (1978) Labeled 2-deoxy-d-glucose analogs. ¹⁸F-labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and ¹⁴C–2-deoxy-2-fluoro-d-glucose. J Label Compd Radiopharm 14:175–184CrossRef

13.

Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, Oster ZH, Sacker DF, Shiue CY, Turner H, Wan CN, Wolf AP, Zabinski SV (1980) A fluorinated glucose analog, 2-fluoro-2-deoxy-d-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 21(7):670–675PubMed

14.

Hamacher K, Coenen HH, Stoecklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[¹⁸F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235–238PubMed

15.

Gómez-Vallejo V, Gaja V, Koziorowski J, Llop J (2012) Specific activity of 11C-labelled radiotracers: a big challenge for PET radiochemists. In: Hsieh CH (ed.) Positron emission tomography—current clinical and research aspects, ISBN 798-953-307-824-3, InTech

16.

Lapi SE, Welch MJ (2012) A historical perspective on the specific activity of radiopharmaceuticals: what have we learned in the 35 years of the ISRC. Nucl Med Biol 39(5):601–608PubMedCrossRef

17.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST (2008) Skeltal PET with ¹⁸F-fluoride: applying new technology to an old tracer. J Nucl Med 49(1):68–78PubMedCrossRef

18.

Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M (2004) [¹⁸F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15(1):61–69PubMedCrossRef

19.

Notni J, Pohle K, Wester HJ (2013) Be spoilt for choice with radiolabelled RGD peptides: preclinical evaluation of ⁶⁸Ga-TRAP(RGD)₃. Nucl Med Biol 40(1):33–41

20.

Pohle K, Notni J, Bussemer J, Kessler H, Schwaiger M, Beer AJ (2012) ⁶⁸Ga-NODAGA-RGD is a suitable substitute for ¹⁸F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process. Nucl Med Biol 39(6):777–784PubMedCrossRef

21.

Scott PJH (2009) Methods for the incorporation of carbon-11 to generate radiopharmaceuticals for PET imaging. Angew Chem Int Ed 48:6001–6004CrossRef

22.

Banister S, Roeda D, Dolle F, Kassiou M (2010) Fluorine-18 chemistry for PET: a concise introduction. Curr Radiopharm 3(2):68–80CrossRef

23.

Coenen HH, Elsinga PH, Iwata R, Kilbourn MR, Pillai MRA, Rajan MGR, Wagner HN Jr, Zaknun JJ (2010) Fluorine-18 radiopharmaceuticals beyond [¹⁸F]FDG for use in oncology and neurosciences. Nucl Med Biol 37:727–740PubMedCrossRef

24.

Anderson CJ, Ferdani R (2009) Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 24(4):379–393PubMedCrossRef

25.

Ma MT, Donnelly PS (2011) Peptide targeted copper-64 radiopharmaceuticals. Curr Top Med Chem 11(5):500–520PubMedCrossRef

26.

Wolfe RR (1992) Radioactive and stable isotope tracers in biomedicine: principles and practice of kinetic analysis. John Wiley and Sons, New York. ISBN: 0471561312, 9780471561316

27.

International Atomic Energy Agency (2012) Radiation protection of patient (RCOP). https://rpop.iaea.org/RPOP/RPoP/Content/InformationFor/HealthProfessionals/6_OtherClinicalSpecialities/PETCTscan.htm

28.

Singhal T, Narayanan TK, Jain V, Mukherjee J, Mantil J (2008) ¹¹C-l-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10(1):1–18PubMedCrossRef

29.

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[¹⁸F]fluoroethyl)-l-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33(3):287–294PubMedCrossRef

30.

Grosu AL, Weber WA (2010) PET for radiation treatment planning of brain tumours. Radiother Oncol 96(3):325–327PubMedCrossRef

31.

Murphy RC, Kawashima A, Peller PJ (2011) The utility of ¹¹C-choline PET/CT for imaging prostate cancer: a pictorial guide. Am J Roentgenol 196(6):1390–1398CrossRef

32.

Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I (2012) ¹⁸F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 15(1):45–55PubMedCrossRef

33.

Soloviev D, Lewis D, Honess D, Aboagye (2012) [¹⁸F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment. Eur J Cancer 48(4):416–424PubMedCrossRef

34.

Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, Cherel M, Faivre-Chauvet A (2011) Contribution of [⁶⁴Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [¹⁸F]-MISO-a selected review. Nucl Med Rev Cent East Eur 14(2):90–95PubMedCrossRef

35.

Nordberg A, Rinne JO, Kadir A, Långsström B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6:78–87PubMedCrossRef

36.

Matsuda H, Imabayashi E (2012) Molecular neuroimaging in Alzheimer’s disease. Neuroimaging Clin N Am 22(1):57–65PubMedCrossRef

37.

Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46(13):2740–2754PubMedCrossRef

38.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with pittsburgh compound-B. Ann Neurol 55(3):306–319PubMedCrossRef

39.

Cselényi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, Johnström P, Varnäs K, Svensson S, Farde L (2012) Clinical validation of ¹⁸F-AZD4694, an amyloid-β–specific PET radioligand. J Nucl Med 53:415–424PubMedCrossRef

Title: Radiotracers for positron emission tomography imaging
Author: Nic Gillings
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Magnetic Resonance Materials in Physics, Biology and Medicine / Issue 1/2013
Print ISSN: 0968-5243
Electronic ISSN: 1352-8661
DOI: https://doi.org/10.1007/s10334-012-0356-1

At a glance: The STEP trials

Springer Medicine

Radiotracers for positron emission tomography imaging

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

MRI for attenuation correction in PET: methods and challenges

Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction

Physical and organizational provision for installation, regulatory requirements and implementation of a simultaneous hybrid PET/MR-imaging system in an integrated research and clinical setting

Image artifacts from MR-based attenuation correction in clinical, whole-body PET/MRI

In-vivo human brain molecular imaging with a brain-dedicated PET/MRI system

PET/MR for therapy response evaluation in malignant lymphoma: initial experience